Holen Sie sich die Stockscreener-App
4.45
1.83%
0.08
Vorhandelsmarkt:
4.45
Schlusskurs vom Vortag:
$4.37
Offen:
$4.36
24-Stunden-Volumen:
134.00K
Relative Volume:
0.66
Marktkapitalisierung:
$251.65M
Einnahmen:
$34.16M
Nettoeinkommen (Verlust:
$-98.43M
KGV:
-1.9017
EPS:
-2.34
Netto-Cashflow:
$-119.33M
1W Leistung:
+0.23%
1M Leistung:
+0.68%
6M Leistung:
-3.89%
1J Leistung:
-28.91%
1-Tages-Spanne:
$4.36
$4.55
1-Wochen-Bereich:
$4.33
$4.8226
52-Wochen-Spanne:
$2.9448
$6.7899
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Firmenname
Foghorn Therapeutics Inc
Sektor
Branche
Telefon
617-586-3100
Adresse
500 TECHNOLOGY SQUARE, CAMBRIDGE
Vergleichen Sie FHTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
4.45 | 247.13M | 34.16M | -98.43M | -119.33M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-07 | Eingeleitet | Guggenheim | Buy |
| 2025-09-17 | Fortgesetzt | B. Riley Securities | Buy |
| 2025-04-23 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-01-30 | Eingeleitet | B. Riley Securities | Buy |
| 2024-09-03 | Eingeleitet | Jefferies | Buy |
| 2024-08-19 | Eingeleitet | Evercore ISI | Outperform |
| 2023-03-28 | Eingeleitet | BofA Securities | Buy |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-11-17 | Eingeleitet | Cowen | Outperform |
| 2020-11-17 | Eingeleitet | Goldman | Buy |
| 2020-11-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-11-17 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Foghorn Therapeutics Inc Aktie (FHTX) Neueste Nachrichten
Analyst Confidence Rises for Foghorn Therapeutics Following Leadership and Pipeline Updates - AD HOC NEWS
Foghorn Therapeutics (NASDAQ:FHTX) Stock Rating Lowered by Wall Street Zen - Defense World
Is Foghorn Therapeutics Inc. stock attractive for hedge fundsJobs Report & AI Driven Stock Reports - Newser
Stifel Initiates Coverage of Foghorn Therapeutics (FHTX) with Buy Recommendation - Nasdaq
Stifel Initiates Coverage on FHTX with a 'Buy' Rating | FHTX Sto - GuruFocus
Foghorn Therapeutics Inc appoints Jeff Sacher as interim CFO - marketscreener.com
Foghorn Therapeutics appoints Jeff Sacher as interim CFO and treasurer By Investing.com - Investing.com Nigeria
Foghorn Therapeutics appoints Jeff Sacher as interim CFO and treasurer - Investing.com
Foghorn Therapeutics Appoints Interim CFO Jeff Sacher - TipRanks
Why Foghorn Therapeutics Inc. stock remains on buy listsJuly 2025 Price Swings & Reliable Momentum Entry Alerts - Newser
Stifel initiates Foghorn Therapeutics stock with Buy rating, $12 target By Investing.com - Investing.com South Africa
Stifel initiates Foghorn Therapeutics stock with Buy rating, $12 target - Investing.com
R/R Acute Myeloid Leukemia Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Foghorn Therapeutics, AB Science, Oncoceutics, Sanofi - Barchart.com
Foghorn Therapeutics appoints interim CFO Jeff Sacher - MSN
Published on: 2025-12-02 00:54:46 - Newser
Volatility Watch: Will Foghorn Therapeutics Inc stock deliver better than expected guidanceBond Market & Verified Momentum Stock Ideas - BỘ NỘI VỤ
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Recommendation of “Buy” from Analysts - Defense World
What analysts say about Foghorn Therapeutics Inc stockMarket Sentiment Extremes & Maximum Profit Growth - earlytimes.in
Foghorn Therapeutics (NASDAQ:FHTX) Upgraded at Wall Street Zen - MarketBeat
Foghorn Therapeutics CEO joins Evercore Healthcare Conference - Traders Union
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference - The Manila Times
Foghorn Therapeutics (Nasdaq: FHTX) to Join 8th Evercore Healthcare Conference - Stock Titan
Why Foghorn Therapeutics Inc. stock is a must watch in 2025Quarterly Performance Summary & Fast Moving Market Watchlists - newser.com
Can Foghorn Therapeutics Inc. stock maintain growth trajectory2025 Performance Recap & Risk Controlled Daily Plans - newser.com
How Foghorn Therapeutics Inc. stock reacts to Fed rate cutsJuly 2025 Momentum & Weekly Market Pulse Alerts - newser.com
How Foghorn Therapeutics Inc. stock valuations compare to rivalsQuarterly Portfolio Report & Consistent Profit Trading Strategies - newser.com
Is Foghorn Therapeutics Inc. stock safe for conservative investorsQuarterly Portfolio Report & Verified Momentum Watchlists - newser.com
Is Foghorn Therapeutics Inc. stock bottoming outShare Buyback & Fast Gain Stock Tips - newser.com
Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 133.27% as Wall Street Analysts Expect? - Zacks Investment Research
FHTX: SMARCA2 program advances with Lilly partnership; multiple novel assets near IND and strong funding - TradingView
Identifying reversal signals in Foghorn Therapeutics Inc.July 2025 Action & AI Enhanced Trading Signals - newser.com
How Foghorn Therapeutics Inc. stock compares to growth peers2025 Top Gainers & Smart Investment Allocation Tips - newser.com
Check Out Foghorn Therapeutics Inc (FHTX)’s Trade Data Rather Than the Analysts’ Views - Setenews
4DMT Appoints Kristian Humer as Chief Financial Officer - GlobeNewswire Inc.
Finanzdaten der Foghorn Therapeutics Inc-Aktie (FHTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):